Europe’s Generic Drugmakers Say They May Cut Output Due to Energy Bills
A sign marks Novartis' Institutes for Biomedical Research in Cambridge, Mass., on Jan. 2, 2020. (Brian Snyder/Reuters)
A sign marks Novartis' Institutes for Biomedical Research in Cambridge, Mass., on Jan. 2, 2020. (Brian Snyder/Reuters)